Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States.

Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States. Urol Oncol. 2015 Nov; 33(11):496.e11-6.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.